"alpha-Synuclein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synuclein that is a major component of LEWY BODIES that plays a role in neurodegeneration and neuroprotection.
| Descriptor ID |
D051844
|
| MeSH Number(s) |
D12.776.631.860.500 D12.776.637.500
|
| Concept/Terms |
alpha-Synuclein- alpha-Synuclein
- alpha Synuclein
- Non-AB Component of AD Amyloid Protein
- Non AB Component of AD Amyloid Protein
|
Below are MeSH descriptors whose meaning is more general than "alpha-Synuclein".
Below are MeSH descriptors whose meaning is more specific than "alpha-Synuclein".
This graph shows the total number of publications written about "alpha-Synuclein" by people in this website by year, and whether "alpha-Synuclein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 4 | 6 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 4 | 0 | 4 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 4 | 1 | 5 |
| 2018 | 8 | 0 | 8 |
| 2019 | 5 | 3 | 8 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 3 | 6 |
| 2022 | 2 | 1 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 3 | 1 | 4 |
| 2025 | 1 | 2 | 3 |
| 2026 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Condensate State as Determinant of Amyloid Pathology in Neurodegeneration. Biomolecules. 2026 Apr 10; 16(4).
-
Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks. Neurobiol Dis. 2026 05; 222:107364.
-
Tubulin transforms Tau and a-synuclein condensates from pathological to physiological. Nat Commun. 2026 Mar 03; 17(1).
-
a-synuclein preformed fibrils suppress cell cycle progression and glycolytic flux in glioblastoma cells. Exp Cell Res. 2026 Apr 15; 457(2):114970.
-
Modulation of a-Synuclein Oligomer and Aggregate Populations by pH and Metal Ions. Biomolecules. 2026 02 20; 16(2).
-
Assessment of Angiopep-2 targeting intracerebral a-synuclein aggregates in a PFF-induced rat model of Parkinson's disease based on 7T CEST-MRI. Brain Res Bull. 2026 Apr; 237:111783.
-
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder. Ann Neurol. 2025 09; 98(3):482-491.
-
Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits. eNeuro. 2025 Apr; 12(4).
-
Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson's disease. Cell Rep. 2025 Mar 25; 44(3):115355.
-
Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics. ACS Chem Neurosci. 2024 11 06; 15(21):3915-3931.